Sarah Whelan, PhD
Science Writer
at Technology Networks
Sarah joined Technology Networks in 2022 after completing a PhD in cancer biology, where her research focused on the development of colon cancers. In her role as science writer and editor, Sarah covers scientific news and a range of other content types, leading the site's coverage of drug discovery, biopharma and cancer research content.
Education
Areas of Expertise
Got a Question for Sarah Whelan, PhD?
Get in touch using the contact form linked here and we’ll get back to you shortly.
Published Content
Total: 309
Infographic
Host Cell Protein Analysis: Approaches and Advances
Biopharmaceuticals and biotherapeutics are medicines produced from living cells. But cells produce other proteins (called host cell proteins, or HCPs) that can contaminate the final therapeutic product and cause a number of problems.
Article
How Is AI Being Used in Drug Discovery?
This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.
Industry Insight
Research Partnership Aims To Advance Fragment-Based Cancer Drug Discovery
Cancer Research Horizons and Diamond Light Source aim to strengthen their partnership, combining their expertise and resources to bring new cancer treatments to patients.
News
Bacteria Could Be Targets for a Colon Cancer Vaccine
Two bacterial strains may be linked to higher rates of colon cancer in some countries. This may provide a target for the development of measures such as vaccines to cut rates of colon cancer.
News
Weight Loss Drug Shrinks Heart Muscle in Mice and Human Cells
Weight loss drugs like semaglutide may shrink heart muscle as well as waistlines, according to a new study. It found that the popular drug decreased heart muscle mass in lean and obese mice.
News
Obesity and Diabetes Drugs Could Help To Protect the Kidneys
New research from The George Institute of Global Health shows that a popular class of obesity and type 2 diabetes drugs can reduce a person’s risk of kidney deterioration and failure regardless of whether they have type 2 diabetes or not.
Industry Insight
How Diverse Mouse Models Can Drive Drug Discovery Innovation
We spoke to Prof. Nadia Rosenthal, to find out more about their new approach and how using genetically diverse mice that better reflect human diversity can help find better therapies for a variety of diseases.
News
Short-Term Menopausal Hormone Therapy Has No Lasting Cognitive Effects
Short-term menopausal hormone therapy (mHT) does not have long-term cognitive effects when given to women in early postmenopause, according to new research from Mayo Clinic scientists.
News
Beta-Blockers Linked to Depression for Some Heart Attack Patients
Commonly prescribed beta-blockers may increase the risk of depression for some patients who have had heart attacks, but also have a normal heart pumping ability, new research from Uppsala University suggests.
Industry Insight
How Can We Design Clinical Trials for Older People? We Asked an Expert
At ELRIG Drug Discovery 2024, Technology Networks sat down with Miles Witham, professor of trials for older people at Newcastle University, to learn more about these challenges and how novel approaches can be used to improve current research.
Advertisement
